Oni-Orisan Akin, Kristiansen Lars V, Haroutunian Vahram, Meador-Woodruff James H, McCullumsmith Robert E
Wayne State University School of Medicine, Detroit, Michigan, USA.
Biol Psychiatry. 2008 Apr 15;63(8):766-75. doi: 10.1016/j.biopsych.2007.10.020. Epub 2007 Dec 26.
Schizophrenia is a chronic, severe mental illness with profound emotional and economic burdens for those afflicted and their families. An increasing number of studies have found that schizophrenia is marked by dysregulation of glutamatergic neurotransmission. While numerous studies have found alterations of postsynaptic molecules in schizophrenia, a growing body of evidence implicates presynaptic factors. Vesicular glutamate transporters (VGLUTs) have been identified and are known to package glutamate into vesicles in the presynaptic terminal for subsequent release into the synaptic cleft. Recent studies have shown that VGLUTs regulate synaptic activity via the amount of glutamate released. Accordingly, we hypothesized that VGLUTs are altered in schizophrenia, contributing to dysfunction of presynaptic activity.
Using in situ hybridization and Western blot analysis, we investigated alterations in VGLUT1 and VGLUT2 transcript and protein expression in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and a comparison group.
We found increased VGLUT1 transcript and reduced VGLUT1 protein expression in the ACC, but not DLPFC, in schizophrenia. Vesicular glutamate transporter 2 was unchanged at both levels of gene expression. We did not find changes in VGLUT1 messenger RNA (mRNA) or protein levels following 28-day treatment of rats with haloperidol (2 mg/kg/day), suggesting that our findings in schizophrenia are not due to an effect of antipsychotic treatment.
Overall, our data suggest decreased glutamate release in the ACC, as well as discordant regulation of VGLUT1 expression at different levels of gene expression.
精神分裂症是一种慢性、严重的精神疾病,给患者及其家庭带来沉重的情感和经济负担。越来越多的研究发现,精神分裂症的特征是谷氨酸能神经传递失调。虽然众多研究已发现精神分裂症患者突触后分子存在改变,但越来越多的证据表明突触前因素也有影响。囊泡谷氨酸转运体(VGLUTs)已被识别,其作用是将谷氨酸包装到突触前终末的囊泡中,随后释放到突触间隙。最近的研究表明,VGLUTs通过释放的谷氨酸量来调节突触活动。因此,我们推测精神分裂症患者的VGLUTs发生改变,导致突触前活动功能障碍。
我们使用原位杂交和蛋白质印迹分析,研究了精神分裂症患者及对照组在前扣带回皮质(ACC)和背外侧前额叶皮质(DLPFC)中VGLUT1和VGLUT2转录本及蛋白表达的变化。
我们发现,精神分裂症患者的ACC中VGLUT1转录本增加而VGLUT1蛋白表达减少,但DLPFC中未出现此情况。囊泡谷氨酸转运体2在基因表达的两个水平上均未改变。用氟哌啶醇(2毫克/千克/天)对大鼠进行28天治疗后,我们未发现VGLUT1信使核糖核酸(mRNA)或蛋白水平有变化,这表明我们在精神分裂症患者中的发现并非抗精神病药物治疗的结果。
总体而言,我们的数据表明ACC中谷氨酸释放减少,以及VGLUT1在不同基因表达水平上的调节不一致。